Literature DB >> 2259448

Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.

H Tohgi1, T Abe, S Takahashi, J Takahashi, M Ueno, Y Nozaki.   

Abstract

We studied the effect of a synthetic norepinephrine precursor, L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) on the total (conjugated and unconjugated) norepinephrine concentrations in the cerebrospinal fluid (CSF) of 6 parkinsonian patients with freezing phenomenon. The total norepinephrine concentrations in the CSF increased from 5- to 75-fold after treatment with L-threo-DOPS. The degree of increase in the norepinephrine (NE) concentrations was closely correlated to the dosage of L-threo-DOPS. The freezing phenomenon improved in 3 out of 6 patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2259448     DOI: 10.1016/0304-3940(90)90409-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

2.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18

Review 3.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

4.  Effects of Manipulation of Noradrenergic Activities on the Expression of Dopaminergic Phenotypes in Aged Rat Brains.

Authors:  Fei Zeng; Yan Fan; Russell W Brown; Wesley Drew Gill; Jennifer B Price; Thomas C Jones; Meng-Yang Zhu
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

5.  Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.

Authors:  Robert A Hauser; Stephane Heritier; Gerald J Rowse; L Arthur Hewitt; Stuart H Isaacson
Journal:  Clin Neuropharmacol       Date:  2016 Sep-Oct       Impact factor: 1.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.